Such agreements and other government measures that use most-favored-nation pricing targets for prescription drugs, including the use of international pricing reference to set drug prices in the U.S., or increases generic and biosimilar drug entry sooner than expected, can have a material adverse effect on our industry, the ability to set adequate pricing for new drugs to recover R&D costs, and the ability to attract potential investors and potential buyers in the future.
